KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Invested Capital (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Invested Capital for 9 consecutive years, with -$116.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 75.34% year-over-year to -$116.4 million, compared with a TTM value of -$116.4 million through Dec 2025, up 75.34%, and an annual FY2025 reading of -$116.4 million, up 75.34% over the prior year.
  • Invested Capital was -$116.4 million for Q4 2025 at Biocryst Pharmaceuticals, down from $3.2 million in the prior quarter.
  • Across five years, Invested Capital topped out at $3.2 million in Q3 2025 and bottomed at -$472.0 million in Q1 2024.
  • Average Invested Capital over 3 years is -$322.6 million, with a median of -$423.3 million recorded in 2023.
  • The sharpest move saw Invested Capital plummeted 437.39% in 2024, then surged 100.73% in 2025.
  • Year by year, Invested Capital stood at -$451.1 million in 2023, then fell by 4.63% to -$472.0 million in 2024, then surged by 75.34% to -$116.4 million in 2025.
  • Business Quant data shows Invested Capital for BCRX at -$116.4 million in Q4 2025, $3.2 million in Q3 2025, and -$385.9 million in Q2 2025.